EXCLUSIVE: Disney Entertainment Television has chosen its participants for the 2025-26 Directing and Writing Programs, talent development initiatives which connect emerging writers and directors with ...

Regeneron is adding its name to Tessera Therapeutics’ unique in vivo gene-writing program, inking a deal that lets it in on a prospect for alpha-1 antitrypsin deficiency (AATD) through a $150 million ...

A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...

The Eclipse IDE is remarkably simple to install on a Windows 10 or 11 computer. To install Eclipse on Windows, simply follow the five steps outlined in this video: Download the Eclipse IDE zip file ...

The debate about ChatGPT’s use of the em dash signifies a shift in not only how we write, but what writing is for. By Nitsuh Abebe There are countless signals you might look for to determine whether a ...

Woods College of Advancing Studies offers a low-residency Master of Arts in Creative Writing that helps you write with depth and purpose. With an interdisciplinary approach that combines psychology, ...

The Hechinger Report covers one topic: education. Sign up for our newsletters to have stories delivered to your inbox. Consider becoming a member to support our nonprofit journalism. Of course, no one ...

A hacker has exploited a leading artificial intelligence chatbot to conduct the most comprehensive and lucrative AI cybercriminal operation known to date, using it to do everything from find targets ...

In August 2025, internet users shared a rumor that U.S. President Donald Trump had capped housing rental assistance to two years. The measure was a real part of the discretionary budget proposal for ...

With hundreds of degree options across various disciplines and colleges, choosing which graduate program you’ll pursue is no small task. Here are some questions to consider as you narrow your choices ...

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first participant in the ECLIPSE 2 Phase 3 clinical trial, which is designed to compare the ...